Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Pujol

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation StudyJean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trialElisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Radiology|March 7, 2025
Multicenter external validation of a novel aggregated technique for percutaneous CT guided lung biopsy for multiple samplings: the ExtraPEARL studyMarco Calandri, Jacopo Brino, Steven Yevich, et al.
The Journal of Clinical Investigation|November 1, 2019
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinomaEmilie Bousquet Mur, Sara Bernardo, Laura Papon, et al.
Bulletin Du Cancer|November 21, 2002
[2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer]Jeanne-Marie Bréchot, Thierry Molina, Serge Theobald, et al.
EMBO Molecular Medicine|January 16, 2026
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinumSara Bernardo, Lisa Brunet, Quentin Dominique Thomas, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
Lancet (London, England)|January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation StudyJean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trialElisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Radiology|March 7, 2025
Multicenter external validation of a novel aggregated technique for percutaneous CT guided lung biopsy for multiple samplings: the ExtraPEARL studyMarco Calandri, Jacopo Brino, Steven Yevich, et al.
The Journal of Clinical Investigation|November 1, 2019
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinomaEmilie Bousquet Mur, Sara Bernardo, Laura Papon, et al.
Bulletin Du Cancer|November 21, 2002
[2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer]Jeanne-Marie Bréchot, Thierry Molina, Serge Theobald, et al.
EMBO Molecular Medicine|January 16, 2026
NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinumSara Bernardo, Lisa Brunet, Quentin Dominique Thomas, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
Lancet (London, England)|January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
The New England Journal of Medicine|May 15, 2024
Perioperative Nivolumab in Resectable Lung CancerTina Cascone, Mark M Awad, Jonathan D Spicer, et al.
Pageof 10